Last 48 quarters of trend data · Healthcare · Specialty & Generic Drugs
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -37.62 | — | — | 22.52 | — | — | — | — | — | 36.74 | — | 31.69 | — | 9.13 | 11.34 | 12.66 | 3.35 | 7.34 | 10.07 | 8.24 | — |
| — | — | — | — | — | — | — | — | — | +302.4% | — | +150.3% | — | +24.3% | +12.7% | +53.6% | — | -43.6% | — | — | — | |
| P/S Ratio | 1.57 | 1.36 | 1.23 | 1.13 | 0.97 | 0.77 | 0.73 | 0.80 | 1.05 | 0.93 | 0.83 | 0.99 | 0.85 | 0.76 | 0.77 | 0.78 | 0.88 | 0.64 | 0.77 | 0.79 | 0.94 |
| — | +77.0% | +68.2% | +41.5% | -8.0% | -17.5% | -12.3% | -19.0% | +24.3% | +23.0% | +8.8% | +26.8% | -3.4% | +18.7% | -1.0% | -1.2% | -6.9% | -29.7% | -18.0% | -17.3% | -14.7% | |
| P/B Ratio | 1.58 | 1.49 | 1.30 | 1.08 | 0.98 | 0.76 | 0.67 | 0.66 | 0.80 | 0.70 | 0.65 | 0.72 | 0.64 | 0.57 | 0.58 | 0.55 | 0.65 | 0.54 | 0.64 | 0.65 | 0.80 |
| — | +96.3% | +92.6% | +63.2% | +22.4% | +7.6% | +3.7% | -8.0% | +25.5% | +23.4% | +12.6% | +30.2% | -1.6% | +5.5% | -10.4% | -14.1% | -19.2% | -30.4% | -21.0% | -18.1% | +14.5% | |
| P/FCF | 11.36 | 6.25 | 14.04 | 11.39 | 6.52 | 4.47 | 15.81 | 5.66 | 11.28 | 4.70 | 9.88 | 6.40 | 11.67 | 4.07 | 7.05 | 3.26 | — | 3.44 | 4.47 | 3.09 | 13.56 |
| — | +40.0% | -11.2% | +101.5% | -42.2% | -5.0% | +60.0% | -11.7% | -3.3% | +15.6% | +40.2% | +96.3% | — | +18.1% | +57.8% | +5.5% | — | -20.0% | -51.4% | -41.6% | — | |
| EV / EBITDA | 13.36 | 8.38 | 11.50 | 12.02 | 13.82 | 6.72 | 6.77 | — | 12.55 | 7.84 | 13.33 | 8.84 | 39.99 | 6.46 | 7.16 | 6.67 | 11.92 | 5.95 | 6.56 | 6.02 | 14.51 |
| — | +24.7% | +69.9% | — | +10.1% | -14.3% | -49.2% | — | -68.6% | +21.4% | +86.1% | +32.6% | +235.6% | +8.5% | +9.1% | +10.7% | -17.9% | -17.0% | -19.4% | -31.8% | -89.9% | |
| EV / EBIT | — | 33.44 | 137.62 | — | — | 56.56 | — | — | — | 29.73 | — | 23.06 | — | 13.44 | 15.86 | 16.03 | 4.93 | 12.91 | 15.58 | 12.90 | — |
| — | -40.9% | — | — | — | +90.2% | — | — | — | +121.3% | — | +43.8% | — | +4.1% | +1.8% | +24.3% | — | -53.9% | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 35.1% | 38.4% | 38.8% | 32.9% | 30.6% | 36.8% | 37.2% | 35.7% | 34.4% | 38.9% | 38.1% | 41.1% | 41.6% | 42.9% | 41.1% | 41.4% | 32.9% | 42.9% | 41.4% | 42.3% | 35.6% |
| — | +4.1% | +4.2% | -7.8% | -11.1% | -5.3% | -2.3% | -13.1% | -17.2% | -9.3% | -7.3% | -0.7% | +26.6% | +0.1% | -0.8% | -2.1% | -7.7% | +23.6% | +42.7% | +66.1% | +82.7% | |
| Operating Margin | -18.6% | 7.0% | 0.2% | -2.3% | -7.2% | 6.7% | 6.5% | -88.6% | -5.1% | 6.0% | -6.3% | 5.6% | -11.8% | 11.5% | 9.4% | 10.7% | -5.2% | 13.7% | 13.3% | 16.9% | -1.8% |
| — | +4.2% | -97.4% | +97.4% | -40.7% | +11.1% | +202.9% | -1691.2% | +57.0% | -47.4% | -167.1% | -48.1% | -128.1% | -16.6% | -29.3% | -36.5% | -190.6% | +74.2% | +1376.4% | +380.9% | +92.6% | |
| Net Margin | -24.6% | -8.7% | -3.2% | 5.0% | -9.2% | -3.4% | -0.1% | -93.5% | -14.6% | 2.5% | -8.6% | 3.1% | -20.0% | 8.4% | 6.7% | 6.0% | 26.1% | 8.7% | 7.6% | 9.5% | -6.1% |
| — | -154.4% | -2362.9% | +105.4% | +37.3% | -234.9% | +98.5% | -3106.5% | +26.6% | -70.0% | -227.6% | -48.4% | -176.5% | -3.2% | -11.6% | -36.7% | +529.4% | +26.5% | +225.0% | +140.7% | +76.0% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -21.1% | -2.3% | -0.8% | 1.2% | -2.3% | -0.8% | -0.0% | -17.7% | -2.7% | 0.5% | -1.7% | 0.6% | -3.7% | 1.6% | 1.3% | 1.1% | 5.0% | 1.8% | 1.6% | 2.0% | -1.3% |
| — | -179.6% | -2685.1% | +106.8% | +15.5% | -272.7% | +98.2% | -3253.5% | +27.4% | -69.7% | -230.6% | -47.4% | -173.7% | -12.5% | -19.0% | -45.1% | +496.5% | +23.5% | +219.0% | +141.7% | +75.4% | |
| ROA | -8.9% | -0.9% | -0.3% | 0.5% | -0.9% | -0.3% | -0.0% | -7.6% | -1.2% | 0.2% | -0.7% | 0.2% | -1.6% | 0.7% | 0.5% | 0.5% | 2.0% | 0.7% | 0.6% | 0.7% | -0.5% |
| — | -177.8% | -2655.0% | +106.3% | +24.4% | -259.6% | +98.3% | -3273.7% | +24.6% | -69.1% | -230.7% | -47.0% | -177.5% | -4.2% | -10.2% | -38.6% | +530.8% | +30.0% | +225.7% | +142.8% | +75.9% | |
| ROIC | -6.6% | 0.7% | 0.0% | -0.2% | -0.7% | 0.6% | 0.6% | -7.0% | -0.4% | 0.5% | -0.5% | 0.4% | -0.9% | 0.9% | 0.7% | 0.8% | -0.4% | 1.1% | 1.0% | 1.2% | -0.1% |
| — | +16.3% | -97.1% | +96.9% | -71.3% | +32.6% | +220.2% | -1823.4% | +54.5% | -44.7% | -169.7% | -46.5% | -132.0% | -17.3% | -29.4% | -38.9% | -189.9% | +76.8% | +1362.6% | +392.2% | +92.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.00 | 0.99 | 0.96 | 1.00 | 1.00 | 0.97 | 0.95 | 0.92 | 0.77 | 0.81 | 0.89 | 0.91 | 0.90 | 0.89 | 0.90 | 0.91 | 0.93 | 1.06 | 1.07 | 1.09 | 1.14 |
| — | +2.6% | +0.8% | +7.9% | +30.2% | +19.5% | +6.5% | +1.5% | -14.5% | -9.3% | -1.6% | +0.1% | -3.1% | -15.5% | -15.8% | -16.6% | -18.7% | -6.1% | -7.8% | -5.6% | +0.0% | |
| Debt / EBITDA | 108.74 | 14.17 | 20.08 | 24.50 | 29.33 | 15.65 | 16.19 | — | 25.26 | 17.89 | 31.81 | 20.35 | 96.74 | 16.47 | 17.86 | 16.84 | 29.21 | 16.08 | 16.73 | 15.45 | 34.75 |
| — | -9.5% | +24.0% | — | +16.1% | -12.5% | -49.1% | — | -73.9% | +8.6% | +78.1% | +20.8% | +231.2% | +2.4% | +6.7% | +9.0% | -15.9% | -7.0% | -14.0% | -27.8% | -90.4% | |
| Current Ratio | 1.30 | 1.55 | 1.58 | 1.60 | 1.30 | 1.35 | 1.37 | 1.68 | 1.65 | 1.51 | 1.53 | 1.67 | 1.67 | 1.60 | 1.50 | 1.58 | 1.58 | 1.61 | 1.46 | 1.22 | 1.10 |
| — | +14.8% | +15.6% | -4.7% | -21.1% | -10.2% | -10.4% | +1.0% | -1.3% | -5.9% | +2.1% | +5.6% | +5.8% | -0.5% | +3.0% | +29.5% | +42.9% | +43.7% | +25.5% | -1.3% | -9.5% | |
| Quick Ratio | 0.74 | 0.97 | 0.96 | 1.03 | 0.74 | 0.79 | 0.77 | 0.97 | 0.98 | 0.96 | 1.02 | 1.17 | 1.22 | 1.06 | 0.94 | 0.98 | 1.05 | 1.09 | 0.98 | 0.82 | 0.70 |
| — | +22.9% | +24.9% | +6.2% | -24.9% | -17.5% | -24.1% | -17.6% | -19.8% | -9.5% | +8.3% | +20.1% | +15.9% | -2.5% | -4.5% | +18.5% | +50.6% | +52.4% | +37.4% | +11.5% | +0.1% | |
| Interest Coverage | -6.78 | 2.14 | 0.47 | -0.27 | -1.87 | 0.93 | -0.86 | -25.81 | -3.38 | 1.62 | -1.69 | 2.48 | -5.07 | 3.84 | 3.32 | 3.20 | 10.99 | 3.79 | 3.67 | 4.61 | -0.38 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying VTRS stock.
Viatris Inc.'s current P/E is -37.6x. The average P/E over the last 1 quarters is 22.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Viatris Inc.'s current operating margin is -18.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Viatris Inc.'s business trajectory between earnings reports.